A striking statistical finding from a major Ontario cohort study reveals the numerical weight of prescribing duration: benzodiazepine prescriptions longer than 30 days reduced discontinuation likelihood by 74% compared to prescriptions of 7 days or fewer. This adjusted hazard ratio of 0.26 represents one of the strongest associations between initial prescribing decision and long-term medication trajectory. The dose-response relationship is clear and consistent: prescriptions of 8–14 days lowered discontinuation by 46%, while 15–30 day prescriptions reduced it by 65%. Among nearly 1.8 million incident benzodiazepine users tracked between 2013 and 2021, the data paint a compelling picture of how a single clinical decision—prescription duration at initiation—can substantially influence whether a patient remains on benzodiazepines long-term. The evidence suggests that adherence to shorter initial prescriptions, as recommended by clinical guidelines, may be one of the most practical and immediately actionable steps to mitigate dependence risk. Read the full article on GMJ Newsroom.
Was this article helpful?
